Evidence map›Paper›PMID 33072781›Full record

SynthesisFrontiers in medicine2020

The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.

Marco Canevelli, Giulia Remoli, Federica Trentin, Gabriele Riccardi, Leonardo Tariciotti, Giovanni Risoleo, Antonio Ancidoni, Giuseppe Bruno, Matteo Cesari, Nicola Vanacore and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marco CanevelliNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Giulia RemoliDepartment of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
Federica TrentinDepartment of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
Gabriele RiccardiDepartment of Sense Organ, Sapienza University of Rome, Rome, Italy.
Leonardo TariciottiUnit of Neurosurgery, IRCSS Fondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Giovanni RisoleoDepartment of Radiology, ASTT Grande Ospedale Metropolitano Niguarda, University of Milan, Milan, Italy.
Antonio AncidoniNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Giuseppe BrunoDepartment of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
Matteo CesariDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Nicola VanacoreNational Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
Valeria RaparelliDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this disease currently relies on supportive care and the off-label and compassionate use of antivirals and immunomodulators. Nevertheless, there has been a great worldwide effort to progress research and test the efficacy and safety/tolerability profiles of numerous candidate agents that may positively affect the various clinical syndromes associated with COVID-19. In parallel, vaccination and chemoprophylaxis strategies are being investigated. This article provides a summary of interventional studies targeting COVID-19 during the emergency phase of the outbreak to broadly inform clinicians and researchers on what happened and what they can expect in upcoming months. The clinicaltrials.gov database and the European Union (EU) Clinical Trials Register were investigated on March 31, 2020, to identify all ongoing phase 1-4 research protocols testing pharmacological interventions targeting SARS-CoV-2 infection and/or clinical syndromes associated with COVID-19. Overall, six phase 1, four phase 1-2, 14 phase 2, ten phase 2-3, 19 phase 3, and nine phase 4 studies were identified, and the features of these studies are described in the present review. We also provide an updated overview of the change overtime in the pipeline following this emergency phase and based on the current epidemiology of the COVID-19 pandemic.

Indexed as

antiviralsclinical trialsCOVID-19drug developmentimmunomodulatorsresearch protocolsSARS-CoV-2

Identifiers

PMID33072781
PMCPMC7542224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.